COVID-19 - December 4, 2020
Pfizer and BioNTech achieve first authorization in the world for a COVID-19 vaccine
Pfizer and BioNTech have announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK has granted a temporary authorization for emergency use for their mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. Pfizer and […]
COVID-19 - November 9, 2020
Promising results from Pfizer and BioNTech’s vaccine trial
Pfizer and BioNTech have announced that their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. The […]
COVID-19 - August 4, 2020
Early positive update from Pfizer and BioNTech vaccine study
BioNTech and Pfizer has announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are available on an online preprint server at medRxiv and are concurrently undergoing scientific peer-review for potential publication. Preliminary data The preliminary clinical results are for […]
COVID-19 - July 6, 2020
Pfizer and BioNTech announces early data from vaccine candidate study
Pfizer and BioNTech has announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. Overall, the preliminary data demonstrated that […]
COVID-19 - March 17, 2020
Pfizer and BioNTech to co-develop potential COVID-19 vaccine
Pfizer and BioNTech have announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together. “This is a […]
